Last reviewed · How we verify
Furosemide Injection, USP
At a glance
| Generic name | Furosemide Injection, USP |
|---|---|
| Also known as | IV furosemide |
| Sponsor | SQ Innovation, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy Volunteers (PHASE1)
- Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure (PHASE2, PHASE3)
- Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure (PHASE1, PHASE2)
- Sub-Q Versus IV Furosemide in Acute Heart Failure (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Furosemide Injection, USP CI brief — competitive landscape report
- Furosemide Injection, USP updates RSS · CI watch RSS
- SQ Innovation, Inc. portfolio CI